Medpace Holdings (NASDAQ: MEDP) reported Q2 EPS of $1.06, $0.07 better than the analyst estimate of $0.99. Revenue for the quarter came in at $278.3 million versus the consensus estimate of $272.1 million.

GUIDANCE:

Medpace Holdings sees FY2021 EPS of $4.31-$4.50, versus the consensus of $4.38. Medpace Holdings sees FY2021 revenue of $1.11-1.15 billion, versus the consensus of $1.13 billion.

• The Company forecasts 2021 revenue in the range of $1.110 billion to $1.150 billion, representing growth of 19.9% to 24.2% over 2020 revenue of $925.9 million. GAAP net income for full year 2021 is forecasted in the range of $162.5 million to $169.5 million. Additionally, full year 2021 EBITDA is expected in the range of $205.0 million to $215.0 million. Based on forecasted 2021 revenue of $1.110 billion to $1.150 billion and GAAP net income of $162.5 million to $169.5 million, diluted earnings per share (GAAP) is forecasted in the range of $4.31 to $4.50. This guidance assumes a full year 2021 tax rate of 11.0% to 12.0% and does not reflect the potential impact of any share repurchases the Company may make pursuant to the share repurchase program after June 30, 2021.

For earnings history and earnings-related data on Medpace Holdings (MEDP) click here.